NLS Pharmaceutics AG
23.1.2023 14:33:52 CET | ACCESS Newswire | Press release
- The orexin deficit is believed to be the root cause of narcolepsy
- Mazindol ER is the most advanced Orexin-2 partial receptor agonist in development for the treatment of narcolepsy and other rare sleep disorders
- Mazindol ER is a first in class, unique dual mechanism of action as pan-monoamine reuptake inhibitor and strong Orexin-2 partial receptor agonist
- Phase 2 clinical trials evaluating Quilience (mazindol ER) in the treatment of narcolepsy recently concluded, meeting the primary endpoint with high statistical significance
ZURICH, SWITZERLAND / ACCESSWIRE / January 23, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced new in vitro study results demonstrating the agonist effect of mazindol ER at the Orexin-2 Receptor (OX2R). Two identical studies measuring differing concentrations of mazindol ER confirmed significant OX2R partial agonist activity at 30μM or higher. Notably, findings show that mazindol ER showed strong OX2R partial agonist activity by cellular and nuclear receptor functional assays. Results showed pEC50 (a logarithm measure of drug potency expressing a concentration that is effective in producing 50% of the maximal response) values of 4.7 to 5 for mazindol on the OX2R, indicating a strong OX2R partial agonist.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Orexin, also known as hypocretin, is a neuropeptide that regulates arousal, wakefulness, and appetite. Orexin plays a critical role in regulating the sleep-wake cycle and the most common form of narcolepsy, type 1 (NT1), in which the individual experiences brief losses of muscle tone, known as or cataplexy, is caused by a lack of orexin in the brain due to destruction of the cells that produce it. Mazindol ER is an OX2R partial agonist that was developed to address the loss of orexin signaling in NT1. Currently available treatments for NT1 only address the associated symptoms but not the underlying loss of orexin.
"This result is very encouraging for understanding the mechanism of action of mazindol ER in the treatment of narcolepsy," said Eric Konofal, MD, PhD, Chief Scientific Officer of NLS Pharmaceutics. "This is a significant add-on therapeutic option in narcolepsy type 1 that includes excessive daytime sleepiness and the sudden loss of muscle tone, or cataplexy, when a person is awake. We now know that orexin is considered to play a crucial role in the sleep-wake cycle and narcolepsy is caused by severe loss of the orexin neurotransmitter in the lateral hypothalamus."
Additional pre-clinical in vivo studies are currently underway to confirm OX2R activity. A pilot study in OXR2 KO mice animal model compared favorably with investigational drug, TAK-925, an orexin 2 receptor agonist. Supplementary studies to further characterize OX2R activity as well as activity at OX1R are planned for the first half of 2023. NLS Pharmaceutics plans to present the study results at a scientific meeting later this year.
"The unique dual mechanism of action of mazindol ER seems to represent an advantage over previously studied compounds, as mazindol ER appears to be highly effective in reducing narcolepsy symptoms without the potential side effects of a full OX2R agonist. We are very optimistic about these studies combined with the promising results of our phase 2 program," said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics.
The Phase 3 program for Quilience (mazindol ER) is currently on track to commence in mid- 2023.
About NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.
About Quilience®
The Company's lead product candidate, Quilience®, is a proprietary extended-release formulation of mazindol (mazindol ER) and is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders such as Idiopathic Hypersomnia (IH), for which NLS recently obtained Orphan Disease Designation (ODD) from the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Mazindol is a triple monoamine reuptake inhibitor and partial Orexin-2 Receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. A Phase 2 multi-center U.S. clinical study evaluating Quilience® in adult patients suffering from narcolepsy met its primary endpoint with high statistical significance and demonstrated a favorable safety and tolerability profile. NLS also successfully completed a Phase 2 study in the U.S. evaluating Nolazol® (Mazindol Controlled-Release) in adult patients suffering from ADHD. The study met all primary and secondary endpoints and Nolazol® was well-tolerated. Quilience® has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy. Up to 1/3 of narcoleptic patients are also diagnosed with ADHD.
Safe Harbor Statement
This press release contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS is using forward-looking statements when it discusses that mazindol ER appears to be highly effective in reducing narcolepsy symptoms without the potential side effects of a full OX2R agonist, the ability of mazindol ER to treat narcolepsy and the timing of the Phase 3 program for Quilience. These forward-looking statements and their implications are based on the current expectations of the management of NLS only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; NLS may encounter delays or obstacles in launching and/or successfully completing its clinical trials; NLS' products may not be approved by regulatory agencies, NLS' technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; NLS may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with NLS' process; NLS' products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; NLS' patents may not be sufficient; NLS' products may harm recipients; changes in legislation may adversely impact NLS; inability to timely develop and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of NLS to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, NLS undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading "Risk Factors" in NLS' annual report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC), which is available on the SEC's website, www.sec.gov, and in subsequent filings made by NLS with the SEC.
For additional information:
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
www.nlspharmaceutics.com
SOURCE: NLS Pharmaceutics AG
View source version on accesswire.com:
https://www.accesswire.com/736231/NLS-Pharmaceutics-Announces-New-In-Vitro-Data-Reconfirming-QuiliencesR-Mazindol-ER-Unique-Dual-Mechanism-of-Action-Involving-Significant-Orexin-2-Receptor-Activity
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI Achieves New Milestone With Semi-Autonomous CCA Flight12.2.2026 21:55:00 CET | Press release
YFQ-42A Uncrewed Fighter Jet Executes Mission Autonomy Test SAN DIEGO, CA / ACCESS Newswire / February 12, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) passed a new milestone this month, successfully integrating 3rd-party mission autonomy into the YFQ-42A Collaborative Combat Aircraft to conduct its first semi-autonomous airborne mission. For this test, GA-ASI used mission autonomy software supplied by Collins Aerospace, an RTX business, to fly the new YFQ-42A CCA, designed and developed by GA-ASI for the U.S. Air Force. The Sidekick Collaborative Mission Autonomy software was seamlessly integrated with the YFQ-42A's flight control system, utilizing the Autonomy Government Reference Architecture (A-GRA). The integration enabled robust and reliable data exchange between the autonomy software and the aircraft's mission systems, ensuring precise execution of mission autonomy commands. During the recent testing, autonomy mode was activated via the Ground Station Console (GSC)
Loar Holdings Inc. Announces Date and Time for Fourth Quarter and Full Year 2025 Earnings Conference Call12.2.2026 14:30:00 CET | Press release
WHITE PLAINS, NEW YORK / ACCESS Newswire / February 12, 2026 / Loar Holdings Inc. (NYSE:LOAR), will report Q4 and Full Year 2025 earnings before the market opens on Thursday, February 26, 2026. A conference call will follow at 10:30a.m., Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website; https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar
U.S. Polo Assn. Unveils Experiential USPA Shop Flagship at the USPA National Polo Center12.2.2026 13:00:00 CET | Press release
WEST PALM BEACH, FLORIDA / ACCESS Newswire / February 12, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), announces the reopening of its experiential USPA Shop Flagship at the USPA National Polo Center (NPC) in Wellington, Florida. The sports brand is introducing a reimagined retail destination that reflects the brand's deep connection to the sport of polo and its modern global positioning.The USPA Shop Flagship at the USPA National Polo Center Photo Credit: Augustina Fonda The USPA Shop at NPC now places a strong emphasis on the guest experience. Inside and out, the space is complemented by refined visuals, immersive activations, curated sound, a signature scent, and a best-in-class assortment of apparel and accessories from the brand's design hubs of New York, London, Florence, and Istanbul. The refreshed design of the flagship location blends heritage, sport, and contemporary style, incorporating signature U.S. Polo Assn. elements such
Fidelity Investments Upgrades FINOS Membership to Platinum, Reinforcing Its Strategic Commitment to Open Source Collaboration in Financial Services11.2.2026 15:00:00 CET | Press release
Following its leadership in launching Fluxnova, Fidelity's appointment to the FINOS Governing Board underscores the growing recognition of the ROI of open source for all market participants NEW YORK CITY, NY / ACCESS Newswire / February 11, 2026 / The Fintech Open Source Foundation (FINOS), the foundation of open innovation in financial services, today announced that Fidelity Investments has upgraded its FINOS membership to Platinum, reflecting Fidelity's deepening strategic commitment to open source collaboration, industry interoperability, and the responsible adoption of emerging technologies such as AI across regulated financial services. The membership upgrade builds directly on Fidelity's role in the formation of Fluxnova, a FINOS-hosted open source orchestration platform created to address critical industry needs around workflow automation, vendor independence, and long-term infrastructure sustainability. Fidelity spearheaded the project's contribution into FINOS, helping establi
U.S. Marine Corps Selects GA-ASI for MUX TACAIR Collaborative Combat Aircraft Program10.2.2026 21:00:00 CET | Press release
GA-ASI's YFQ-42A Platform to Support Next-Generation Expeditionary Air Operations SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 10, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) was competitively selected by the U.S. Marine Corps (USMC) for evaluation in the Marine Air-Ground Task Force Uncrewed Expeditionary Tactical Aircraft (MUX TACAIR) Collaborative Combat Aircraft (CCA) program. The agreement integrates GA-ASI's expertise in autonomy and uncrewed aircraft systems with a government-provided mission package, usingthe YFQ-42A platform as a surrogate to evaluate integration with crewed fighters. The contract initiates integration of a Marine Corps mission kit into the YFQ-42A surrogate platform for assessment within the Marine Air Ground Task Force (MAGTF). The USMC contract includes the rapid development of autonomy for the government-supplied mission kit - a cost-effective, sensor-rich, software-defined suite capable of delivering kinetic and non-kinetic effects -
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
